Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia

Among patients with relapsed CBF-AML, median survival was less than a year and half and the outcome was worse in patients with t (8;21). Despite the relatively better outcomes, dedicated clinical trials are needed to improve the outcome in all patients with relapsed CBF-AML.